Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation-Reference-Cited by-同舟云学术

Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation

Published:2010-04-06 Issue:7 Volume:38 Page:1166-1176
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Sweeny David J.,Li Weiqun,Clough Jeffrey,Bhamidipati Somasekhar,Singh Rajinder,Park Gary,Baluom Muhammad,Grossbard Elliott,Lau David T.-W.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference26 articles.

1. Lignans and Human Health

2. Importance of tetrahydrofolate and ATP in the anaerobic O-demethylation reaction for phenylmethylethers;Berman;Appl Environ Microbiol,1992

3. R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

4. Metabolism and Disposition of Dasatinib after Oral Administration to Humans

5. Intestinal Bacterial Communities That Produce Active Estrogen-Like Compounds Enterodiol and Enterolactone in Humans

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microbial metabolism marvels: a comprehensive review of microbial drug transformation capabilities;Gut Microbes;2024-08-16

2. Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers;ACS Medicinal Chemistry Letters;2024-04-18

3. Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates;Chemical Society Reviews;2024

4. Fostamatinib: a novel treatment for idiopathic thrombocytopenic purpura;Japanese Journal of Thrombosis and Hemostasis;2024

5. Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor;Journal of Pharmacology and Experimental Therapeutics;2023-11-02